Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
VYNE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-3.08
vs -2.34
Q3.23
N/A
-1.85
vs -2.88
Q4.23
N/A
-0.20
vs -2.60
Q1.24
N/A
-0.15
vs -1.74
Q2.24
N/A
-0.22
vs -3.08
Q3.24
N/A
-0.29
vs -1.85
Q4.24
N/A
-0.28
vs -0.20
Q1.25
N/A
-0.20
vs -0.15
Q2.25
N/A
-0.22
vs -0.22
Q3.25
N/A
-0.23
vs -0.29
Sales Growth
YoY
Current
Estimates
Q2.23
+7%
135K vs 126K
Q3.23
-32%
114K vs 167K
Q4.23
+1167%
76K vs 6K
Q1.24
-1%
98K vs 99K
Q2.24
+47%
198K vs 135K
Q3.24
+6%
121K vs 114K
Q4.24
+11%
84K vs 76K
Q1.25
+106%
202K vs 98K
Q2.25
-24%
150K vs 198K
Q3.25
+45%
175K vs 121K
Return on Equity
QoQ
Q2.23
-58%
-0.58
vs -0.21
Q3.23
-57%
-0.57
vs -0.58
Q4.23
-7%
-0.07
vs -0.57
Q1.24
-7%
-0.07
vs -0.07
Q2.24
-13%
-0.13
vs -0.07
Q3.24
-19%
-0.19
vs -0.13
Q4.24
-23%
-0.23
vs -0.19
Q1.25
-20%
-0.20
vs -0.23
Institutionnal Ownership
QoQ
Q2.23
20
20
vs 21
-5%
Q3.23
21
21
vs 20
5%
Q4.23
33
33
vs 21
57%
Q1.24
32
32
vs 33
-3%
Q2.24
32
32
vs 32
NA
Q3.24
32
32
vs 32
NA
Q4.24
35
35
vs 32
9%
Q1.25
38
38
vs 35
9%
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
benzinga.com
11 hours ago
Forecast
123%2026-Revenue
-268%2026-EPS
95%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Relative Strength
VYNE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.25 ( 15.15%)
Relative Strenght
16
Volume Buzz
136%
Earning Acce
Yes
Dist 52w H.
56%